country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P9960

Copy Link Print Information

Biologically Validated

Ocrelizumab

Name: Ocrelizumab
Brand: MedChemExpress
SKU: HY-P9960
Price: 300.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: 2H7; PRO70769; RG1594)

Avis client

Based on 1 Customer Validation

Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: ≥99.0%
CAS No.: 637334-45-3
Masse moléculaire:145.82 kDa

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Ocrelizumab Chemical Structure

CAS No.: 637334-45-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
- Verified Bioactivity
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

CD20/MS4A1

In Vivo

Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)^[1].
Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

HuCD20 mice with chronic DTH-TLS lesions^[1].
Dosage:

7.5 mg/kg
Administration:

Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction
Result:

Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice.

Animal Model:

C57BL/6 mice ^[2].
Dosage:

50 μg
Administration:

Intravenous injection (i.v.); repeat administration on days 7, 14, and 21
Result:

Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

931 [NCBI]

Accession

P11836

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Ocrelizumab. The EC₅₀ for this effect is 19.79 ng/mL.
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ocrelizumab (anti-CD20) (HY-P9960). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/200 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

Chemical Information

CAS No. 637334-45-3
Appearance Liquid
Masse moléculaire 145.82 kDa
Color Colorless to light yellow
SMILES

[Ocrelizumab]
Synonyms

2H7; PRO70769; RG1594
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (260 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Torres JB, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. [Content Brief]

[2]. Schubart A, et al. Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T-and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice (P2. 410)[J]. Neurology, 2018, 90(15_supplement): P2. 410.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Application
- Biological Activity
Chemical Information
Pureté et documentation
Références

1/16

Human IgG1 kappa
1/16

Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Ocrelizumab. The EC₅₀ for this effect is 19.79 ng/mL.
1/16

Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ocrelizumab (anti-CD20) (HY-P9960). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/200 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
1/16

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ocrelizumab

Protein A Agarose

Bradford Protein Assay Kit

Cell-ATP Viability Detection Kit

HOLO Human Interleukin-2 (IL-2) Detection Kit

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)